Optimizing the use of anti-tumor necrosis factor in the management of patients with Crohn’s disease
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Optimizing the use of anti-tumor necrosis factor in the management of patients with Crohn’s disease
Authors
Keywords
-
Journal
Therapeutic Advances in Chronic Disease
Volume 6, Issue 3, Pages 147-154
Publisher
SAGE Publications
Online
2015-04-07
DOI
10.1177/2040622315579621
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 566 Infliximab Concentration and Clinical Outcome in Patients With Ulcerative Colitis
- (2015) Walter Reinisch et al. GASTROENTEROLOGY
- 565 Novel Infliximab (IFX) and Antibody-to-Infliximab (ATI) Assays are Predictive of Disease Activity in Patients With Crohn's Disease (CD)
- (2015) Brian G. Feagan et al. GASTROENTEROLOGY
- Sa2047 Association of Serum Infliximab and Antibodies to Infliximab to Long-Term Clinical Outcome in Acute Ulcerative Colitis
- (2015) Sanjay Murthy et al. GASTROENTEROLOGY
- 1159 Results on the Optimisation Phase of the Prospective Controlled Trough Level Adapted Infliximab Treatment (TAXIT) Trial
- (2015) Niels Vande Casteele et al. GASTROENTEROLOGY
- 492 Trough Levels and Antidrug Antibodies Predict Safety and Success of Restarting Infliximab After a Long Drug Holiday
- (2015) Filip J. Baert et al. GASTROENTEROLOGY
- Tu1147 Serum Adalimumab Levels and Antibodies Correlate With Endoscopic Intestinal Inflammation and Inflammatory Markers in Patients With Inflammatory Bowel Disease
- (2015) Andres J. Yarur et al. GASTROENTEROLOGY
- 979 Impact of Concomitant Immunomodulator Treatment on Efficacy and Safety of Anti-TNF Therapy in Crohn's Disease: A Meta-Analysis of Placebo Controlled Trials With Individual Patient-Level Data
- (2015) Jennifer Jones et al. GASTROENTEROLOGY
- Sa1195 Exposure-Efficacy Relationship (ER) for Adalimumab During Induction Phase of Treatment of Adult Patients With Moderate to Severe Ulcerative Colitis
- (2015) Nael M. Mostafa et al. GASTROENTEROLOGY
- 490 Prevalence of Antibodies to Adalimumab (ATA) and Correlation Between Ata and Low Serum Drug Concentration on CRP and Clinical Symptoms in a Prospective Sample of IBD Patients
- (2015) Fernando S. Velayos et al. GASTROENTEROLOGY
- Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial
- (2014) Casper Steenholdt et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Antitumor necrosis factor α is more effective than conventional medical therapy for the prevention of postoperative recurrence of Crohn’s disease
- (2014) Douglas L. Nguyen et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- 788 Higher 6-Thioguanine Nucleotide Concentrations Are Associated With Higher Trough Levels of Infliximab in Patients on Combination Therapy
- (2014) Andres Yarur et al. GASTROENTEROLOGY
- Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD
- (2014) Parambir S Dulai et al. GUT
- Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
- (2013) Niels Vande Casteele et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Optimizing anti-TNF treatments in inflammatory bowel disease
- (2013) Shomron Ben-Horin et al. AUTOIMMUNITY REVIEWS
- A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab
- (2013) Fernando S. Velayos et al. Clinical Gastroenterology and Hepatology
- Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease
- (2013) Brian G. Feagan et al. GASTROENTEROLOGY
- Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial
- (2013) Casper Steenholdt et al. GUT
- Serum Adalimumab Concentration and Clinical Remission in Patients with Crohnʼs Disease
- (2013) Yi-Lin Chiu et al. INFLAMMATORY BOWEL DISEASES
- Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis
- (2012) Kavinderjit S Nanda et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Review article: loss of response to anti-TNF treatments in Crohn’s disease
- (2011) S. Ben-Horin et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Review article: remission rates achievable by current therapies for inflammatory bowel disease
- (2011) L. Peyrin-Biroulet et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review
- (2011) Vincent Billioud et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies
- (2011) Uri Kopylov et al. INFLAMMATORY BOWEL DISEASES
- Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
- (2010) Waqqas Afif et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
- (2009) Javier P Gisbert et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis
- (2009) Corey A. Siegel et al. Clinical Gastroenterology and Hepatology
- Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
- (2009) Konstantinos Karmiris et al. GASTROENTEROLOGY
- Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease
- (2008) R. L. WEST et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial
- (2008) Gert Van Assche et al. GASTROENTEROLOGY
- Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines
- (2008) S Ben-Horin et al. GUT
- Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
- (2008) Geert D'Haens et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now